23 results
424B5
QLGN
Qualigen Therapeutics Inc
1 Dec 21
Prospectus supplement for primary offering
2:28pm
by other factors, including:
severity of the disease under investigation;
Qualigen’s ability to recruit clinical trial investigators of appropriate … its facilities and continue to recruit and train additional qualified personnel. Qualigen may not be able to effectively manage the expansion of its
10-KT
QLGN
Qualigen Therapeutics Inc
31 Mar 21
Annual report (with FYE transition)
4:33pm
growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit … and train additional qualified personnel. We may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
424B5
zpd05ym p2hm
18 Dec 20
Prospectus supplement for primary offering
1:26pm
424B5
uemfk
2 Oct 20
Prospectus supplement for primary offering
4:24pm
424B5
xzuk9qh3
4 Aug 20
Prospectus supplement for primary offering
6:16am
424B5
llop kgldcazn9a2pc
10 Jul 20
Prospectus supplement for primary offering
2:35pm
424B3
9xc8sw7anefc 5g8t2
9 Apr 20
Prospectus supplement
9:30am
S-4/A
jxl 9pili074iq3fbpx9
13 Mar 20
Registration of securities issued in business combination transactions (amended)
5:28pm
S-4
jknree
4 Feb 20
Registration of securities issued in business combination transactions
6:26am
8-K
EX-10.2
j7f42 xrx2tri8ovnq
2 Jul 18
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
6:01am
8-K
EX-10.1
ib6 p12fs42z
7 May 18
Entry into a Material Definitive Agreement
6:03am
10-K
uedlws9gijl0z3h 7z
21 Mar 16
Annual report
12:00am